A Rare Case of Small Cell Lung Cancer With an Epidermal Growth Factor Receptor Mutation and Its Response to Osimertinib

Small cell lung cancer (SCLC) accounts for less than 15% of the cases of lung cancer. Epidermal growth factor receptor (EGFR) mutations are rarely reported in association with SCLC. EGFR tyrosine kinase inhibitors (TKI) are approved as the first-line therapy for metastatic non-small cell lung cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhuiyan, Sakil, Siddiqui, Raheel S, Zirkiyeva, Milana, Agladze, Mariam, Bashir, Tayyaba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214366/
https://www.ncbi.nlm.nih.gov/pubmed/34164239
http://dx.doi.org/10.7759/cureus.15136
_version_ 1783710049361723392
author Bhuiyan, Sakil
Siddiqui, Raheel S
Zirkiyeva, Milana
Agladze, Mariam
Bashir, Tayyaba
author_facet Bhuiyan, Sakil
Siddiqui, Raheel S
Zirkiyeva, Milana
Agladze, Mariam
Bashir, Tayyaba
author_sort Bhuiyan, Sakil
collection PubMed
description Small cell lung cancer (SCLC) accounts for less than 15% of the cases of lung cancer. Epidermal growth factor receptor (EGFR) mutations are rarely reported in association with SCLC. EGFR tyrosine kinase inhibitors (TKI) are approved as the first-line therapy for metastatic non-small cell lung cancer (NSCLC). The clinical effect of EGFR mutations and its response to osimertinib are unknown in SCLC. We report a case of EGFR-positive metastatic SCLC in a 63-year-old female who was treated with the third-generation TKI, osimertinib. 
format Online
Article
Text
id pubmed-8214366
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-82143662021-06-22 A Rare Case of Small Cell Lung Cancer With an Epidermal Growth Factor Receptor Mutation and Its Response to Osimertinib Bhuiyan, Sakil Siddiqui, Raheel S Zirkiyeva, Milana Agladze, Mariam Bashir, Tayyaba Cureus Internal Medicine Small cell lung cancer (SCLC) accounts for less than 15% of the cases of lung cancer. Epidermal growth factor receptor (EGFR) mutations are rarely reported in association with SCLC. EGFR tyrosine kinase inhibitors (TKI) are approved as the first-line therapy for metastatic non-small cell lung cancer (NSCLC). The clinical effect of EGFR mutations and its response to osimertinib are unknown in SCLC. We report a case of EGFR-positive metastatic SCLC in a 63-year-old female who was treated with the third-generation TKI, osimertinib.  Cureus 2021-05-20 /pmc/articles/PMC8214366/ /pubmed/34164239 http://dx.doi.org/10.7759/cureus.15136 Text en Copyright © 2021, Bhuiyan et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Bhuiyan, Sakil
Siddiqui, Raheel S
Zirkiyeva, Milana
Agladze, Mariam
Bashir, Tayyaba
A Rare Case of Small Cell Lung Cancer With an Epidermal Growth Factor Receptor Mutation and Its Response to Osimertinib
title A Rare Case of Small Cell Lung Cancer With an Epidermal Growth Factor Receptor Mutation and Its Response to Osimertinib
title_full A Rare Case of Small Cell Lung Cancer With an Epidermal Growth Factor Receptor Mutation and Its Response to Osimertinib
title_fullStr A Rare Case of Small Cell Lung Cancer With an Epidermal Growth Factor Receptor Mutation and Its Response to Osimertinib
title_full_unstemmed A Rare Case of Small Cell Lung Cancer With an Epidermal Growth Factor Receptor Mutation and Its Response to Osimertinib
title_short A Rare Case of Small Cell Lung Cancer With an Epidermal Growth Factor Receptor Mutation and Its Response to Osimertinib
title_sort rare case of small cell lung cancer with an epidermal growth factor receptor mutation and its response to osimertinib
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214366/
https://www.ncbi.nlm.nih.gov/pubmed/34164239
http://dx.doi.org/10.7759/cureus.15136
work_keys_str_mv AT bhuiyansakil ararecaseofsmallcelllungcancerwithanepidermalgrowthfactorreceptormutationanditsresponsetoosimertinib
AT siddiquiraheels ararecaseofsmallcelllungcancerwithanepidermalgrowthfactorreceptormutationanditsresponsetoosimertinib
AT zirkiyevamilana ararecaseofsmallcelllungcancerwithanepidermalgrowthfactorreceptormutationanditsresponsetoosimertinib
AT agladzemariam ararecaseofsmallcelllungcancerwithanepidermalgrowthfactorreceptormutationanditsresponsetoosimertinib
AT bashirtayyaba ararecaseofsmallcelllungcancerwithanepidermalgrowthfactorreceptormutationanditsresponsetoosimertinib
AT bhuiyansakil rarecaseofsmallcelllungcancerwithanepidermalgrowthfactorreceptormutationanditsresponsetoosimertinib
AT siddiquiraheels rarecaseofsmallcelllungcancerwithanepidermalgrowthfactorreceptormutationanditsresponsetoosimertinib
AT zirkiyevamilana rarecaseofsmallcelllungcancerwithanepidermalgrowthfactorreceptormutationanditsresponsetoosimertinib
AT agladzemariam rarecaseofsmallcelllungcancerwithanepidermalgrowthfactorreceptormutationanditsresponsetoosimertinib
AT bashirtayyaba rarecaseofsmallcelllungcancerwithanepidermalgrowthfactorreceptormutationanditsresponsetoosimertinib

Ejemplares similares